



Program - ICTHIC May 27-29, 2022

Friday, May 27th 2022

8:45 – 09:00 Congress Opening: Anna Falanga, Benjamin Brenner, Alok A. Khorana

9:00 – 11:15 Plenary Session 1: Emerging trends in cancer associated thrombosis

Chairs: TBA

1. **Frits Mulder (The Netherlands)**. VTE in cancer in contemporary era
2. **Cliona Kirwan (UK)**. Thrombosis and coagulation in the contemporary management of breast cancer
3. **Grigoris Gerotziafas (France)**. Machine learning for risk stratification of CAT
4. **Kristen M. Sanfilippo (USA)**. Thrombosis and risk stratification in hematological malignancies.

Oral Communications

11:15 – 13:30 Plenary Session 2: Exploring the relationship between hemostasis and cancer: New insights

Chairs: TBA

1. **Ronit Satchi-Fainaro (Israel)**. Hemostatic mechanisms in glioblastoma progression
2. **Simon Mantha (USA)**. Cancer mutations and thromboembolic risk
3. **Axel Rosell (Sweden)**. The role of neutrophil extracellular traps in CAT.
4. **Nina Iversen (Norway)**. Molecular mechanisms of TF/TFPI pathway regulation in tumor cells

Oral Communications

13:30 – 14:30 Lunch sessions 14:30 – 15:00 Coffee and pastries

15:00 – 17:15 Plenary Session 3: Role of hemostatic biomarkers in CAT and cancer progression

Chairs: TBA

1. **Jamie Marie O’Sullivan (Ireland)**. Bi-directional cross talk between coagulation and cancers: current assessment of pre-clinical evidence

2. **Aurélien Delluc (Canada)**. PET scan for occult cancer among patients with unprovoked VTE: what do we know?
3. **Laurence Panicot-Dubois (France)**. The role of platelets in cancer progression
4. **M. Marchetti (Italy)**. Hemostatic system activation in breast cancer: searching for new biomarkers of cancer outcome

Oral Communications

17:15- 17:45 Coffee Break

17:45 – 18:45 DEBATE: Catheter-associated Thrombosis in cancer patients: To prophylaxis or not to prophylaxis?

Chairs: TBA

YES: Marc Carrier (Canada)

NO: Cecilia Becattini (Italy)

18.45 – 19.30 Plenary Lecture: 7th Simon Karpatkin Memorial Lecture

Chairs: Anna Falanga (Italy); Benjamin Brenner (Israel); Alok A Khorana (USA)

Introduction to Lecture: TBA

Joe Palumbo (USA). Haemostatic system, immunity, and Inflammation in Cancer.

19.30 – 20.30 Welcome Reception

Saturday, May 28th 2022

8:30 – 10:45 Plenary session 4: Hemostatic complications and novel anti-cancer therapies

Chairs: TBA

1. **Keith McCrae (USA)**. Old is new again: emergence of thromboembolic complications in cancer patients on immunotherapy
2. **Florian Moik (Austria)**. Emerging data linking thrombosis to targeted anti-cancer treatments
3. **Tzu-Fei Wang (Canada)**. Drug-drug interaction: implications for cancer associated VTE treatment
4. **Rupert Bauersachs (Germany)**. Bleeding risk with direct oral anticoagulants in cancer patients

Oral Communications

10:45 – 12:30 **Poster sessions** with coffee and pastries

12:30 – 13:30 SPECIAL LECTURE:

Chairs: TBA

Maria Luisa Lavitrano (Italy). Importance of biobanking in cancer and thrombosis research: building new 'horizons'

13:30 – 14:30 Lunch sessions

14:30 – 15:00 Coffee and pastries

15:00 – 17:15 Plenary Session 5: COVID-19, thrombosis, and cancer

Chairs: TBA

1. **Nicole Kuderer (USA).** Cancer and COVID-19: where are the data?
2. **Marcel Levi (UK).** COVID-19 associated coagulopathy in cancer
3. **Mandy N Lauw (The Netherlands).** Thrombosis in acute leukemia
4. **JM Connors (USA).** Essentials of Vaccine-induced thrombotic thrombocytopenia

Oral Communications

17:15– 17:45 Coffee

17:45 – 19:00 ROUND TABLE: Multidisciplinary approach in Cardiovascular Oncology

Chairs: TBA

Introduction: **A. Khorana (USA).** Building a CAT Clinic - Real-World Systems Approaches to Prevention and Treatment

Discussants: **B. Brenner (Israel), AJ Kakkar (UK), N. van Es (The Netherlands), I. Elalamy (France), A.J. Munoz (Spain), M.B. Monreal (Spain).**

20.00 Presidential dinner

Sunday, May 29th 2022

8:30 – 10:45 Plenary Session 6: Cardiovascular complications in cancer patients

Chairs: TBA

1. **Hugo Ten Cate (The Netherlands):** Evolving data on cardiovascular complications in cancer
2. **Alexandros D. Tselepis (Greece).** Cardiotoxic effects of antitumor agents: Pathogenetic mechanisms.
3. **Antonella Tufano (Italy).** Optimizing antithrombotic therapy for atrial fibrillation in cancer.
4. **Josè J Fuster (Spain).** Clonal hematopoiesis and cardiovascular complications in cancer patients

Oral Communications

11:45- 12:45 Italian Brunch

10:45 – 11:45 Debate: Duration of VTE treatment beyond 6 months: To continue or not to continue?

Chairs: TBA

YES: Agnes Lee (Canada)

NO: Marcello Di Nisio (Italy)

12:45 – 15:00 Plenary 7: Prevention and treatment of Cancer-Associated Thromboembolism

Chairs: TBA

1. **Anna Falanga (Italy)**. Prevent and Treat VTE in cancer patients: ESMO Guidelines
2. **J Zwicker (USA)**. Survival benefit of warfarin for treatment of CAT
3. **Michails Karamouzis (Greece)**. The impact of thromboprophylaxis on the survival of patients with pancreatic cancer
4. **Avi Leader (Israel)**. Non-Bacterial Thrombotic Endocarditis in cancer patients: diagnosis and management
5. **Simon Noble (UK)**. Risk benefit analysis of anticoagulation in elderly cancer patients

Oral Communications

15:00 – 15:10 Concluding Remarks